Shogo Shigeta

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Nicoletta Colombo, Elena Biagioli, Kenichi Harano et al. · The Lancet Oncology · 2024 · 89 citations

Gynecological Surgery, Medicine, Metronomic Therapy +6

Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer

Satsuki Mashiko, Kazuyuki Kitatani, Masafumi Toyoshima et al. · Cancer Biology & Therapy · 2015 · 61 citations · Full text

Gynecology, Pharmacotherapy, Cancer Biology +17

Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid

Kazuyuki Kitatani, Toshinori Usui, Shravan Kumar Sriraman et al. · Oncogene · 2015 · 52 citations · Full text

Oncology, Chemoprevention Strategy, Metastasis-suppressor Lipid +8

Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer

Xuewei Zhang, Kazuyuki Kitatani, Masafumi Toyoshima et al. · Molecular Cancer Therapeutics · 2017 · 51 citations · Full text

Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer

Shogo Shigeta, Masafumi Toyoshima, Kazuyuki Kitatani et al. · Oncogene · 2015 · 37 citations

Possible Involvement, Dna Double-strand Breaks, Oncogenic Agent +7